NCT06858748Recruiting
Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough
Canadian Consortium for Understanding the Role of Airway Mucus Occlusions in Asthma, COPD and Chronic Cough
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
Chronic lung diseases affect one in five Canadians, causing symptoms such as cough, breathlessness, and wheeze. Despite advancements in medical care, these conditions not only impact individuals and their close circles but also present substantial clinical and economic challenges at a national level. This grant is dedicated to addressing three prevalent lung diseases: asthma, chronic obstructive pulmonary disease (COPD), and chronic cough. An alliance of clinicians, scientists, knowledge users, and patient partners from across Canada have come together to establish the Canadian Consortium for Understanding the Role of Airway Mucus Occlusions in Asthma, COPD, and Chronic Cough - "CANMuc." Mucus plays a pivotal role in the symptoms and severity of lung diseases, but its clinical assessment has been challenging. Fortunately, recent medical advances, particularly chest computed tomography (CT), facilitate visualizing and quantifying mucus in patients with lung diseases. Our goal is to initially assess mucus plugging in a diverse group of Canadians without lung disease and then compare these findings to those with asthma, COPD, and chronic cough. The investigators will recruit 100 healthy volunteers for comprehensive clinical and research evaluations, including sputum analyses, breathing tests, quality of life assessments, cough monitoring, and CT scans. In addition, testing will be conducted twice, two years apart, in 240 adult and 50 pediatric participants. This approach will enable the investigators to understand the burden of mucus and how it changes over time, explore proteins or chemicals in mucus that predict mucus persistence, and identify biomarkers that can help guide physicians to prescribe targeted treatments that might work better than others. The CANMuc team's findings will guide strategies for identifying and treating mucus plugging, inform policymakers, and share knowledge with Canadians living with asthma, COPD, and chronic cough.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 240 (estimated)
- First submitted
- 27 Feb 2025
- Start date
- 11 Dec 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- McMaster University
- NCT number
- NCT06858748
What you commit to
- Study type: Observational
- Planned participants: 240
- From 11 Dec 2025 to the primary completion date, Dec 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of mucolytic medications
- Treatment with current biologic therapy: anti-IgE mAb within 130 days, anti-IL-4/4R, IL-5/5R, IL-13, or TSLP within 2 months or 5 half-lives whichever is longer prior to visit 1
Other illness
- History of other pulmonary disorders
- Memory, cognitive, or psychiatric limitations that may prevent optimal participation
Other
- Pregnant or breastfeeding
- Current smoker or \>10 yr pack history or smoked within the last 6 months
- Exacerbation within 4 weeks of recruitment
- Preterm birth (≤36 weeks gestation) or perinatal complications
- Specialist/Respirologist suspects primary ciliary dyskinesia (PCD)
Who the study is looking for
- Males and females (≥18 years old)
- Asthma: Respiratory physician confirmed diagnosis of moderate-to-severe asthma and Historical objective evidence of asthma and/or specialist/respirologist confirmation (post-bronchodilator reversibility and/or methacholine bronchoprovocation test \<8 mg/mL)
- COPD: Respiratory physician confirmed diagnosis of COPD that is moderate-to-severe according to GOLD criteria (post-bronchodilator FEV1/FVC\<LLN and FEV1\< 80%pred) and CAT score ≥10 or mMRC score ≥ 2
- Chronic cough: Refractory Chronic Cough (RCC) and Unexplained Chronic Cough (UCC) lasting \>1 year with Normal chest radiograph and no airflow obstruction (FEV1/FVC \>Lower Limit of Normal)
- Healthy participants: No history of respiratory disease or other pulmonary disorders and no use of inhaled medications or corticosteroids with normal spirometry and Modified Medical Research Council (mMRC) Dyspnea Scale =\<1
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Joseph's Healthcare Hamilton Coordinator of this site? Confirm its status | Hamilton | Canada | Recruiting |
| Robarts Research Institute Coordinator of this site? Confirm its status | London | Canada | Not yet recruiting |
| McGill University Health Centre Coordinator of this site? Confirm its status | Montreal | Canada | Not yet recruiting |
| The Ottawa Hospital Coordinator of this site? Confirm its status | Ottawa | Canada | Not yet recruiting |
| Quebec Heart and Lung Institute - Laval University Coordinator of this site? Confirm its status | Québec | Canada | Not yet recruiting |
| Université de Sherbrooke Coordinator of this site? Confirm its status | Sherbrooke | Canada | Not yet recruiting |
| St. Paul's Hospital Coordinator of this site? Confirm its status | Vancouver | Canada | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.